NCT01008137已完成4 期
Cell-mediated Immunity Study of H1N1 Influenza A Vaccine With Trivalent Inactivated Influenza Vaccine in Healthy Adults
适应症
干预措施
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 150
- 试验地点
- 1
- 主要终点
- Study the cell-mediated immunity of H1N1 vaccine with seasonal influenza vaccine
研究概览
简要总结
A single center, randomized clinical trial is to be conducted in healthy adults (18-60 years) to evaluate the safety and immunogenicity and study the cell-mediated Immunity of Sinovac's H1N1 influenza A Vaccine (PANFLU.1) with Trivalent Inactivated Influenza Vaccine (ANFLU).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Single (Care Provider)
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy male or female aged between 18 and 60
- •Be able to show legal identity card for the sake of recruitment
- •Volunteers are able to understand and sign the informed consent
排除标准
- •Cases, cured cases and close contact of influenza A (H1N1) virus
- •History of H1N1 vaccine or seasonal influenza vaccine administration
- •Women of pregnancy, lactation or about to be pregnant in 60 days
- •Subject that has a medical history of any of the following: allergic history, or allergic to any ingredient of vaccine, such as egg, egg protein, etc
- •Serious adverse reactions to vaccines such as anaphylaxis, hives, respiratory difficulty, angioedema, or abdominal pain
- •Autoimmune disease or immunodeficiency
- •Asthma that is unstable or required emergent care, hospitalization or intubation during the past two years or that required the use of oral or intravenous corticosteroids
- •Diabetes mellitus (type I or II), with the exception of gestational diabetes
- •History of thyroidectomy or thyroid disease that required medication within the past 12 months
- •Serious angioedema episodes within the previous 3 years or requiring medication in the previous two years
- •Bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulopathy, or platelet disorder requiring special precautions) or significant bruising or bleeding difficulties with IM injections or blood draws
- •Active malignancy or treated malignancy for which there is not reasonable assurance of sustained cure or malignancy that is likely to recur during the period of study
- •Seizure disorder other than:
- •Febrile seizures under the age of two years old
- •Seizures secondary to alcohol withdrawal more than 3 years ago, or
- •A singular seizure not requiring treatment within the last 3 years
- •Asplenia, functional asplenia or any condition resulting in the absence or removal o the spleen
- •Guillain-Barre Syndrome
- •Any history of immunosuppressive medications or cytotoxic medications or inhaled corticosteroids within the past six months (with the exception of corticosteroid nasal spray for allergic rhinitis or topical corticosteroids for an acute uncomplicated dermatitis)
- •History of any blood products within 3 months before the dosing
- •Administration of any other investigational research agents within 30 days before the dosing
- •Administration of any live attenuated vaccine within 30 days before the dosing
- •Administration of subunit or inactivated vaccines, e.g., pneumococcal vaccine, or allergy treatment with antigen injections, within 14 days before the dosing
- •Be receiving anti-TB prophylaxis or therapy currently
- •Axillary temperature > 37.0 centigrade at the time of dosing
- •Psychiatric condition that precludes compliance with the protocol:
- •Past or present psychoses
- •Past or present bipolar disorder requiring therapy that has not been well controlled on medication for the past two years
- •Disorder requiring lithium
- •Suicidal ideation occurring within five years prior to enrollment
- •Any medical, psychiatric, social condition, occupational reason or other responsibility that, in the judgment of the investigator, is a contraindication to protocol participation or impairs a volunteer's ability to give informed consent
研究组 & 干预措施
Group 1: Day 0-PANFLU.1; Day 21-ANFLU
Experimental
50 subjects to receive-Day 0: 15 μg PANFLU.1 vaccine; Day 21: 15 μg ANFLU vaccine.
干预措施: H1N1 influenza A Vaccine (PANFLU.1) (Biological)
Group 3: Day 0-PANFLU.1+ANFLU
Experimental
50 subjects to receive-Day 0: 15 μg PANFLU.1 vaccine+ANFLU vaccine.
干预措施: H1N1 influenza A Vaccine (PANFLU.1) (Biological)
Group 1: Day 0-PANFLU.1; Day 21-ANFLU
Experimental
50 subjects to receive-Day 0: 15 μg PANFLU.1 vaccine; Day 21: 15 μg ANFLU vaccine.
干预措施: Trivalent Inactivated Influenza Vaccine (ANFLU) (Biological)
Group 2: Day 0-ANFLU; Day 21-PANFLU.1
Experimental
50 subjects to receive-Day 0: 15 μg ANFLU vaccine; Day 21: 15 μg PANFLU.1 vaccine.
干预措施: H1N1 influenza A Vaccine (PANFLU.1) (Biological)
Group 2: Day 0-ANFLU; Day 21-PANFLU.1
Experimental
50 subjects to receive-Day 0: 15 μg ANFLU vaccine; Day 21: 15 μg PANFLU.1 vaccine.
干预措施: Trivalent Inactivated Influenza Vaccine (ANFLU) (Biological)
Group 3: Day 0-PANFLU.1+ANFLU
Experimental
50 subjects to receive-Day 0: 15 μg PANFLU.1 vaccine+ANFLU vaccine.
干预措施: Trivalent Inactivated Influenza Vaccine (ANFLU) (Biological)
结局指标
主要结局
Study the cell-mediated immunity of H1N1 vaccine with seasonal influenza vaccine
时间窗: 6 months
次要结局
- Evaluate immunogenicity of H1N1 vaccine with seasonal influenza vaccine in adults(3 months)
- Evaluate safety of H1N1 vaccine with seasonal influenza vaccine in adults(3 months)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Safety and Immunogenicity of an Inactivated Pandemic Influenza VaccinePandemic InfluenzaPreventionNCT00535665Sinovac Biotech Co., Ltd402
已完成
不适用
Laboratory Study of Licensed H1N1 Influenza Vaccines in HIV-1 Perinatally Infected Children and YouthHIV-1 InfectionH1N1FluInfluenzaNCT01484522International Maternal Pediatric Adolescent AIDS Clinical Trials Group149
已完成
2 期
Imiquimod and Influenza Vaccine for Immunocompromised PatientsInfluenza VaccineNCT02960815University of Lausanne Hospitals70
已完成
2 期
Immunogenicity and Safety of a Cell-derived Influenza Vaccine in ElderlyInfluenza VaccinesNCT01013675Abbott Biologicals622
已完成
2 期
Study of SAB-176 in Healthy Adult ParticipantsInfluenza A H1N1NCT04850898SAb Biotherapeutics, Inc.62